Viking Therapeutics names new CFO and COO
7 January 2021 -

Viking Therapeutics Inc, a United States-based clinical-stage biopharmaceutical company, has named Greg Zante as chief financial officer and Marianne Mancini as chief operating officer, it was reported on Wednesday.

Zante has around 25 years of financial management experience at public and private companies in the biotechnology and accounting industries. He has also served as vice president of finance and operations at Viking Therapeutics Inc. He has held the position of chief financial officer at Dance Biopharm and senior positions at several biopharmaceutical companies including Sangamo Therapeutics, Calyx Therapeutics and Matrix Pharmaceuticals.

Mancini joined Viking Therapeutics Inc as vice president of clinical operations. She has also held the position of senior director of clinical operations at Ambit Biosciences Corporation; senior director of clinical operations at Aires Pharmaceuticals Inc and senior director of project management and clinical operations at Arena Pharmaceuticals Inc. She has served in various positions at Baxter BioSciences, Genentech and Procter & Gamble Pharmaceuticals.